Oncology

Join Ipsos for a 30-minute introduction to the complex, fast-moving world of oncology.

The COVID-19 pandemic has been challenging for healthcare systems worldwide – with an already overburdened system and large population, the Indian healthcare system was no exception.

Whilst the global COVID-19 pandemic continued throughout 2021, new oncology drug and indication approvals maintained momentum across the US, Europe and Japan. These included continued roll-out and label expansions of Immuno-Oncology (I-O) therapies, along with treatments approved in Japan ahead of other global regions.

The clinical management of cancer patients has undergone a remarkable evolution in the last 15 years, with the concept of personalised medicine now well-entrenched in the treatment paradigm.

Cancer and cardiovascular (CV) disease kill more people every year than any other illness, including Covid-19.

A Review of 2020 Drug Approvals & Key Milestones

Conquering Complexity, at a Price. This paper will illustrate how disparities in income levels continue to drive far-reaching differences in the way poorer and richer Chinese with cancer are being treated for their disease.

Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.